pharmacokinet metabol nilutamid data avail pharmacokinet metabol nilutamid rat dog human normal volunt patient advanc prostat carcinoma high-perform liquid chromatographi hplc rat bioavail oral rout complet major plasma radioact unchang hour hour clearanc ml/hour/kg bodi weight metabol studi urinari metabolit major metabolit reduct nitro group hydroxylamin primari amino group normal volunt compound linear kinet dose rang mg plasma termin phase forty-thre forty-nin hour studi patient advanc stage prostat carcinoma single-dos kinet kinet repetit twice-daili dose week termin phase plasma unchang nilutamid hour total radioact hour mean SD area curv plasma radioact percent unchang urinari excret radioact slow incomplet collect time regard day metabolit steady-st plasma level nilutamid week human speci plasma decay nilutamid slow elimin metabol single-daili dose appropri hepat impair plasma decay renal impair like littl effect 